

NAMSDL



National Alliance for Model State Drug Laws

OTHER SYNTHETIC SUBSTANCES TRADE NAME AND CHEMICAL COMPOUND CHART

This project was supported by Cooperative Agreement No. 2012-DC-BX-K002 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the office of Juvenile Justice and Delinquency Prevention, the office for Victims of Crime, the Community Capacity Development Office, and the Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the U.S. Department of Justice.

The following chart may not include all trade or other names for the designated substances. It also may not include all variations in the chemical composition of the substance.

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Trade or Other Name	Chemical Compound
2,5-DMA	2,5-dimethoxy-amphetamine; OR 2,5-dimethoxy-amethylphenethylamine
2-AI	2,3-dihydro-1H-inden-2-amine
2-FMA	2-fluoromethamphetamine; OR (RS)-1-(2-fluorophenyl)-N-methylpropan-2-amine
2-MeO-ketamine	methoxyketamine
2C-B	2-(4-bromo-2,5-dimethoxyphenyl)ethanamine; OR 2,5-Dimethoxy-4-bromophenethylamine
2C-C	4-Chloro-2,5-dimethoxyphenethylamine; OR 1-(4-Chloro-2,5-dimethoxyphenyl)-2-aminoethane; OR 1-(4-Chloro-2,5-dimethoxyphenyl)-2-ethanamine; OR 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; OR 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine
2C-D	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; OR 2,5-Dimethoxy-4-methylphenethylamine
2C-E	4-Ethyl-2,5-dimethoxyphenethylamine; OR 2,5-dimethoxy-4-ethylphenethylamine; OR 1-(2,5-Dimethoxy-4-ethylphenyl)-2-aminoethane; OR 2,5-Dimethoxy-4-ethyl-phenethylamine; OR 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
2C-H	2-(2,5-Dimethoxyphenyl)ethanamine; OR 2,5-Dimethoxyphenethylamine
2C-I	4-Iodo-2,5-dimethoxyphenethylamine; OR 2,5-dimethoxy-4-iodophenethylamine; OR 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; OR 4-iodo-2,5-dimethoxy-beta-phenylethylamine
2C-N	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; OR 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine; OR 2,5-Dimethoxy-4-nitrophenethylamine
2C-P	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine; OR 2,5-Dimethoxy-4-propylphenethylamine
2C-T	2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine; OR 4-methylthio-2,5-dimethoxyphenethylamine
2C-B-butterFLY	2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine
2C-B-FLY	2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
2C-B-hemiFLY, 2CB-5-hemiFLY	2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine
2C-B-FLY-NBOMe	N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane
2C-B-NBOMe, 2,5B-NBOMe	2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	bromo-N-(2-methoxybenzyl)phenethylamine
2CBCB-NBOMe	N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
2C-C-NBOMe, 2,5C-NBOMe	2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine
2C-H-NBOMe, 2,5H-NBOMe	2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
2C-I-NBOH, 2,5I-NBOH	N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine
2C-I-NBOMe, 2,5INBOMe, 2,5I-NBOMe, 25I-NBOMe, NBOMe-2C-I, BOM-CI	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine
2C-T-2	2,5-Dimethoxy-4-ethylthiophenethylamine; OR 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
2C-T-4	2,5-Dimethoxy-4-isopropylthiophenethylamine; OR 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
2C-T-7	2,5-Dimethoxy-4-(n)-propylthiophenethylamine; OR 2, 5-Dimethoxy-4-(n)-propylthiophenethylamine; OR 2,5-dimethoxy-4(n) propylthiophenethylamine
2C-TFM-NBOMe	2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
25I-NBF	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine
25I-NBMD, NBMD-2C-I, Cimbi-29	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine
3-HO-PCE	3-[1-(ethylamino)cyclohexyl]phenol
3-HO-PCP	3-hydroxyphencyclidine
3-MeO-PCE	3-Methoxyeticyclidine
3-MeO-PCP	1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine; OR 3-methoxyphencyclidine
3C-B-FLY	2-(4-bromo-2,3,6,7-tetrahydrofurobensofuran-8-yl)-1-methyl-ethylamine
4-AcO-DET	3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate
4-AcO-DMT, OAcetylpsilocin	4-acetoxy-N,N-dimethyltryptamine
4-AcO-DPT	4-acetoxy-N,N-dipropyltryptamine
4-CAB, AEPCA	4-Chlorophenylisobutylamine; OR 1-(4-chlorophenyl)butan-2-amine; OR 4-chloro- α -ethylphenethylamine
4-FA, PAL-303, Flux, Flits, R2D2	para-fluoroamphetamine; OR 4-fluoroamphetamine; OR (RS)-1-(4-Fluorophenyl)propan-2-amine
4-FMA	4-fluoromethamphetamine; OR (RS)-1-(4-fluorophenyl)-N-methylpropan-2-amine
4-HO-DiPT	4-Hydroxy-di-isopropyl-tryptamine; OR 3-[2-(diisopropylamino)ethyl]-1H-indol-4-ol; OR 4-Hydroxy-N,N-

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	diisopropyltryptamine
4-HO-MET	4-hydroxy-N-methyl-N-ethyltryptamine
4-HO-MiPT	3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol
4-HO-MPMI	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydroxyindole
4-HO-MPT	3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol; OR 4-hydroxy-N-methyl-N-propyltryptamine
4-MeO-MiPT	4-methoxy-N-methyl-N-isopropyltryptamine; OR 3-[2-(Isopropylmethylamino)ethyl]-4-methoxyindole
4-MeO-PCP, methoxydine	4-Methoxyphencyclidine; OR 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine
4-methyl-aET	4-Methyl- α -ethyltryptamine; OR 1-ethyl-2-(4-methyl-1H-indol-3-yl)-ethylamine
4-methyl-a-pyrrolidinohexphenone	
5-APB	5-(2-Aminopropyl)benzofuran
5-APDB	5-(2-Aminopropyl)-2,3-dihydrobenzofuran
5-IAI	5-Iodo-2-aminoindane; OR 5-iodo-2,3-dihydro-1H-inden-2-amine
5-ME	5-methyl-ethylone
5-MeO-AMT	1-(5-methoxy-1H-indol-3-yl)propan-2-amine
5-MeO-DALT	N,N-diallyl-5-methoxytryptamine; OR N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine
5-MeO-DET	N,N-Dethyl-5-Methoxytryptamine
5-MeO-DiPT	5-methoxy-diisopropyltryptamine; OR 3-[2-(Diisopropylamino)ethyl]-5-methoxyindole; OR 5-methoxy-N,N-diisopropyltryptamine
5-MeO-DMT	5-methoxy-N,N-dimethyltryptamine; OR 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine; OR 5-methoxy-N,N-dimethyltryptamine; OR 5-methoxy-N,N-dimethyltryptamine; OR 5-methoxy-3-2[2-(dimethylamino)ethyl]indole
5-MeO-DPT	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
5-MeO-MiPT, Moxy, Moxie	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
5-MeO-MPMI	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole
6-APB; Benzofury	6-(2-aminopropyl)benzofuran; OR 1-benzofuran-6-ylpropan-2-amine
6-APDB	6-(2-Aminopropyl)-2,3,-dihydrobenzofuran
7-hydroxymitragynine, Kratom	7-hydroxymitragynine
AMT	Alpha-methyltryptamine
APB	((2-aminopropyl)benzofuran); OR [(2-aminopropyl)benzofuran]; OR (2-aminopropyl)benzofuran

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

APDB	((2-aminopropyl)-2,3-dihydrobenzofuran); OR [(2-aminopropyl)-2,3-dihydrobenzofuran]; OR (2-aminopropyl)-2,3-dihydrobenzofuran
bromo-dragonFLY	1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine; OR bromo-benzodifuranyl-isopropylamine
BTCP	Benzothiophenylcyclohexylpiperidine
Chlorophenylpiperazine, mCPP	meta-chlorophenylpiperazine; OR 1-(3-chlorophenyl)piperazine; OR 3-chlorophenylpiperazine
DiPT	N,N-Diisopropyltryptamine; OR Diisopropyltryptamine; OR N,N-diisopropyltryptamine; OR 3-[2-(diisopropylamino)ethyl]indole
DBP	1,4-Dibenzylpiperazine
DBZP	1,4-dibenzylpiperazine
DET	Diethyltryptamine; OR N,N-Diethyltryptamine
DMT	Dimethyltryptamine
DOB	2,5-Dimethoxy-4-bromoamphetamine; OR 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane
DOC	2,5-Dimethoxy-4-chloroamphetamine; OR 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine; OR 4-chloro-2,5-dimethoxyamphetamine
DOET	2,5-dimethoxy-4-ethylamphetamine
DOI	2,5-dimethoxy-4-iodoamphetamine; OR 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine; OR 4-iodo-2,5-dimethoxyamphetamine
DOM, STP	4-methyl-2,5-dimethoxy-amphetamine
DPT	N,N-Dipropyltryptamine; OR Dipropyltryptamine; OR 3-[2-(dipropylamino)ethyl]indole
Ethyl-ketamine	2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone
Fluoroamphetamine	
Fluoromethamphetamine	
Fluorophenylpiperazine; pFPP; 4-FPP; fluoperazine; flipiperazine	Para-fluorophenylpiperazine; OR 1-(4-fluorophenyl)piperazine
MCPP	1-(3-Chlorophenyl)piperazine
MDEA, MDE	3,4-methylenedioxy-N-ethylamphetamine; OR N-ethylalpha-methyl-3,4(methylenedioxy)phenethylamine
Mescaline-NBOMe	N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine; OR 3,4,5-trimethoxy-N-(2-methoxybenzyl)phenethylamine
Methiopropamine, MPA	1-(thiophen-2-yl)-2-methylaminopropane
Methoxetamine, MXE, 3-MeO-2-Oxo-PCE	(RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone
Methyltryptamine, NMT	N-methyltryptamine; OR 2-(1H-Indol-3-yl)-N-methylethanamine

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

MiPT	N-isopropyl-N-methyltryptamine
MPHP	Methyl-alpha-pyrrolidinohexiophenone; OR Methyl-pyrrolidino-hexanophenone
N,N-dimethylamphetamine	
O-desmethyltramadol, O-DT	3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol
pFPP, 4-FPP	1-(4-Fluorophenyl)piperazine
Phenazepam	7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
pMeOPP, MeOPP	1-(4-Methoxyphenyl)piperazine
PMMA, 4-MMA	para-Methoxy-N-methylamphetamine; OR 4-methoxy-N-methylamphetamine; OR 1-(4-methoxyphenyl)-N-methylpropan-2-amine
pTFMPP	1-[4-(trifluoromethylphenyl)]piperazine
TFMPP	3-trifluoromethylphenylpiperazine; OR 1-[3-(trifluoromethyl)phenyl]piperazine; OR 1-(3-trifluoromethylphenyl) piperazine; OR 1-(3-trifluoromethylphenyl)piperazine; OR 1-(3-[trifluoromethylphenyl])piperazine
TMA	3,4,5-trimethoxy amphetamine

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.